The Scantox Management Team has extensive experience in the CRO industry, pharma, academia and within the field of regulatory compliance. Our focus is bringing the best people on board and develop Scantox to service our clients in the best possible way.
Jeanet Løgsted
PhD, MSc Pharm
Chief Executive Officer
Mikkel Lykke Jensen
DVM
Chief Scientific Officer
Martin Amtoft-Christensen
Chief Financial Officer
Mette Ellemann-Søtofte
MSc Pharm
Chief Operational Officer
Scantox is a GLP-accredited pre-clinical contract research organization originally founded in 1977. Since 2021 Scantox is owned by the Nordic based investment company Impilo. Our focus is on providing high quality work within pharmacology, toxicology and histopathology. We service both global and local partners and are considered world leading within minipig toxicology.
Scantox Group, Headquarters
Hestehavevej 36 A
DK- 4623 Lille Skensved
Denmark (CVR 83090413)
Scantox Sweden – Lund
Medicon Valley, Scheelevägen 2
223 63 Lund, Sweden
Scantox Sweden – Solna
Nobels Väg 16
171 65 Solna, Sweden
